RedHill Biopharma Ltd.
RDHL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $3,498 | $4,796 | $16,003 | $22,523 |
| - Cash | $2,866 | $2,866 | $4,617 | $1,882 |
| + Debt | $214 | $214 | $356 | $356 |
| Enterprise Value | $846 | $2,144 | $11,742 | $20,997 |
| Revenue | $2,039 | $2,039 | $2,736 | $2,736 |
| % Growth | 0% | -25.4% | 0% | – |
| Gross Profit | $1,236 | $1,236 | $1,842 | $1,842 |
| % Margin | 60.6% | 60.6% | 67.3% | 67.3% |
| EBITDA | -$2,105 | -$2,105 | -$1,879 | -$1,817 |
| % Margin | -103.2% | -103.2% | -68.7% | -66.4% |
| Net Income | -$2,067 | -$2,067 | -$2,590 | -$2,590 |
| % Margin | -101.3% | -101.3% | -94.7% | -94.7% |
| EPS Diluted | -1 | -1 | -1 | -1 |
| % Growth | 0% | 0% | 0% | – |
| Operating Cash Flow | -$2,508 | -$2,508 | -$1,592 | -$1,592 |
| Capital Expenditures | -$2 | -$2 | -$4 | -$4 |
| Free Cash Flow | -$2,509 | -$2,509 | -$1,596 | -$1,596 |